Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances. The easiest way to lookup drug information, identify pills, check interactions and set up your own personal medication records. Available for Android and iOS devices. Subscribe to Drugs. This material is provided for educational purposes only and is not intended for medical advice, diagnosis or treatment. We comply with the HONcode standard for trustworthy health information - verify here.
|Published (Last):||2 June 2005|
|PDF File Size:||18.67 Mb|
|ePub File Size:||11.10 Mb|
|Price:||Free* [*Free Regsitration Required]|
Manufacturer: Ferring. Distributor: Zuellig Pharma. Full Prescribing Info. One ampoule of 8. The concentration of the solution is 0.
Pharmacotherapeutic group: Posterior pituitary lobe hormones vasopressin and analogues. Pharmacology: Pharmacodynamics: Terlipressin initially has an effect of its own, but is converted by enzymatic cleavage to lysine vasopressin. Doses of 1 and 2 mg terlipressin acetate effectively reduce the portal venous pressure and produce marked vasoconstriction.
The lowering of portal pressure and azygos blood flow is dependent on dose. The effect of the low dose is reduced after 3 hours, while haemodynamic data show that 2 mg terlipressin acetate is more effective than 1 mg as the higher dose produces a dependable effect throughout the period of treatment 4 hours.
Pharmacokinetics: The pharmacokinetics follows a two-compartment model. It has been found that the half-life is approximately 40 min. The desired concentration of lysine vasopressin in plasma is found initially after approximately 30 min. Toxicology: Preclinical Safety Data: Preclinical data reveal no special hazard for humans based on conventional studies of single- and repeat-dose toxicity, and genotoxicity.
At dosages relevant to humans, the only effects observed in animals were those attributable to the pharmacological activity of terlipressin. No pharmacokinetic data are available from animals to compare with humans the plasma concentrations at which these effects occurred, but as the route of administration was intravenous, a substantial systemic exposure can be assumed for the animal studies.
An embryo-fetal study in rats demonstrated no adverse effects of terlipressin, but in rabbits abortions occurred, probably related to maternal toxicity, and there were ossification anomalies in a small number of fetuses and a single isolated case of cleft palate. No carcinogenicity studies have been performed with terlipressin. Bleeding oesophageal varices.
Treatment of patients with hepatorenal syndrome HRS Type 1 who are actively being considered for liver transplant. The treatment should be maintained until bleeding has been controlled for 24 hours, but up to a maximum of 48 hours.
It is however recommended that the dose not be increased in patients with severe pre-existing cardiovascular disease or in the presence of an ongoing significant adverse event e. Treatment should be continued until about 2 days after the patient achieves HRS reversal SCr less than or equal to The lowest doses used in the clinical studies ranged from 1.
Method of Administration: i. The recommended dose 2 mg terlipressin acetate or 1. Elevated blood pressure in patients with recognised hypertension can be controlled with mcg clonidine i.
Bradycardia requiring treatment should be treated with atropine. Contraindicated in pregnancy. Hypersensitivity to terlipressin or any other excipients of the product. Special Precautions. Blood pressure, heart rate and fluid balance should be monitored during treatment. To avoid local necrosis at the injection site, the injection must be given i. Caution should be exercised in treating patients with hypertension or recognised heart disease.
In patients with septic shock with a low cardiac output terlipressin should not be used. Effects on Ability to Drive and Use Machines: No studies on the effects on the ability to drive and use machines have been performed. Use in Children and the Elderly: Particular caution should be exercised in the treatment of children and elderly patients, as experience is limited in these groups. There are no data available regarding dosage recommendation in these special patient categories.
This medicinal product contains 1. To be taken into consideration in patients on a controlled sodium diet. Cardiovascular Effects: Terlipressin should only be used with caution and under strict monitoring of the patients in the following cases: uncontrolled hypertension; cerebral or peripheral vascular diseases; cardiac arrhythmias; coronary artery disease or previous myocardial infarction.
Terlipressin should not be used in patients with unstable angina or recent acute myocardial infarction. During post-marketing experience, cases of QT interval prolongation and ventricular arrhythmias including "Torsade de pointes" have been reported. In most cases, patients had predisposing factors such as basal prolongation of the QT interval, electrolyte abnormalities hypokalaemia, hypomagnesaemia or medications with concomitant effect on QT prolongation. Therefore, extreme caution should be exercised in the use of terlipressin in patients with a history of QT interval prolongation, electrolytic abnormalities, concomitant medications that can prolong the QT interval, such as class IA and III antiarrhythmics, erythromycin, certain antihistamines and tricyclic antidepressants or medications that can cause hypokalaemia or hypomagnesaemia e.
Ischaemic Events: To avoid local necrosis the injection must be administered intravenously. During post-marketing experience several cases of peripheral ischemia and necrosis unrelated to the injection site have been reported.
Patients with peripheral venous hypertension or morbid obesity seem to have a greater tendency to this reaction. Therefore, extreme caution should be exercised when administering terlipressin in these patients. Respiratory Effects: Terlipressin may cause smooth muscle constriction and should be used with caution and under strict monitoring in patients with severe asthma or chronic obstructive pulmonary disease COPD.
Laboratory Monitoring: During treatment with terlipressin, serum creatinine should be monitored at least daily as terlipressin should be used with caution in patients with renal insufficiency.
Fluid balance and electrolytes should be monitored carefully as hyponatraemia, hypokalaemia, hypomagnesaemia and other electrolyte disturbances have been reported. Pregnancy: Treatment with terlipressin during pregnancy is contraindicated refer Contraindications and Pharmacology: Toxicology: Preclinical safety data under Actions. Terlipressin has been shown to cause uterine contractions and increased intrauterine pressure in early pregnancy and may decrease uterine blood flow.
Terlipressin may have harmful effects on pregnancy and foetus. Spontaneous abortion and malformation has been shown in rabbits after treatment with Terlipressin. Breastfeeding: It is not known whether terlipressin is excreted in human breast milk. The excretion of terlipressin in milk has not been studied in animals. A risk to the suckling child cannot be excluded. Adverse Reactions. The reporting of safety data rely on published literature and post marketing surveillance.
Clinical Trials: Three studies assessed safety as primary outcome in totally patients. Caletti , a prospective, uncontrolled observational study, enrolled patients. The side-effects reported were consistent with the known pharmacological actions of terlipressin. Bruha , a randomised, double-blind study enrolled 25 patients that were randomised to either 5-day or day treatment. Serum sodium and serum creatinine decreased in both arms during treatment, but rose again after discontinuation of treatment.
The hyponatraemia was found to develop rapidly after start of therapy, but was usually reversible with a median recovery time of 4 days after discontinuation of terlipressin. See table. Drug Interactions.
The hypotensive effect of non-selective beta-blockers on the portal vein is increased with terlipressin. Concomitant treatment with medicinal products with a known bradycardic effect e. These effects are due to reflexogenic inhibition of cardiac activity via the vagus nerve due to the elevated blood pressure. Caution For Usage. Special Precautions for Disposal: Any unused drug or waste materials should be disposed of in accordance with local requirements.
Incompatibilities: In the absence of compatibility studies, this medicinal product must not be mixed with other medicinal products. The ampoules are stored in the outer carton in order to protect from light.
Shelf-Life: 2 years. MIMS Class. ATC Classification. H01BA04 - terlipressin ; Belongs to the class of vasopressin and analogues.
Used in posterior pituitary lobe hormone preparations. Regulatory Classification. Exclusive offer for doctors. Sign up for free. Already a member? Sign in.